Amgen (NASDAQ:AMGN) today announced AMJEVITAâ„¢ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.(1,2)“With today’s announcement, AMJEVITA is…